1. Italy Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
DiaSorin S.p.A.

DiaSorin S.p.A.

DSRLF
DiaSorin S.p.A.US flagOther OTC
77.58
USD
-2.82
- -
3.84BMarket Cap
DiaSorin S.p.A.
DSRLF
(Other OTC)

Recent

price

77.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.33
8.02
7.99
8
8.16
9.1
10.38
11.59
12.05
12.91
16.09
21.67
23.57
20.6
22
22.55
16.71
Revenue per Share
1.64
1.81
1.61
1.53
1.55
1.83
2.05
2.54
2.85
3.21
4.53
5.44
4.17
2.87
3.49
2.94
2.7
Basic EPS, GAAP
1.22
1.45
1.43
1.39
1.64
1.94
2.34
2.27
2.83
3.23
4.2
4.96
4.77
3.56
4.44
3.87
4.51
Free Cash Flow per Basic Share
- -
- -
0.46
1.34
0.55
0.6
0.65
0.8
2.62
0.9
0.95
0.96
0.99
1.06
1.14
1.2
- -
Dividend per Share
5.39
2.83
2.64
2.56
2.57
2.85
3.07
3.56
3.86
14.68
17.8
21.38
24.33
3.87
4.53
3.99
- -
Book Value per Share
3.42
4.15
4.42
5.42
6.74
8.55
5.58
7.23
5.97
8.74
10.95
-10.07
-8.23
-6.94
-4.26
-4.02
- -
Tangible Book Value per Share
55
55
54
54
54
55
55
55
56
55
55
57
58
56
54
53
53
Basic Weighted Avg Shares
405
440
434
435
444
499
569
637
669
706
881
1,238
1,361
1,148
1,185
1,195
891
Sales/Revenue/Turnover
35.97
37.34
32.87
31.51
29.65
31.27
31.26
30.99
31.36
31.5
37.46
35.66
27.57
20.71
22.36
22.56
22.18
Operating Margin (%)
22
27
29
28
30
33
45
54
51
59
61
96
153
137
129
128
- -
Depreciation Expense
90
99
87
83
84
100
112
140
158
176
248
311
241
160
188
156
144
Net Income, GAAP
37.61
37.06
36.19
35.74
34.38
33.01
33.04
21.73
22.62
18.75
22.74
22.19
26.33
21.22
22.85
29.1
21.21
Effective Tax Rate (%)
22.35
22.61
20.15
19.09
18.95
20.12
19.74
21.94
23.63
24.88
28.13
25.13
17.7
13.92
15.87
13.02
16.14
Profit Margin (%)
160
188
189
240
309
412
264
344
276
408
554
660
727
663
692
279
- -
Working Capital
21
13
5
- -
- -
- -
24
- -
- -
24
30
1,295
1,232
1,083
967
534
- -
LT Debt
316
350
365
414
484
587
663
742
705
849
956
1,368
1,520
1,538
1,799
1,577
- -
Total Equity
29.3
28.08
23.96
22.02
19.02
19.49
18.34
20.97
21.83
22.51
26.96
18.22
9.82
6.69
7.37
7.35
20.05
Return on Invested Capital (%)
31.51
40.3
53.8
56.33
58.95
67.09
60.37
65.16
71.03
33.56
27.13
18.12
9.94
8.85
15.8
15.86
47.77
Return on Capital (%)
35.62
43.92
58.57
58.84
60.27
67.76
69.22
76.82
77.15
34.55
27.88
28.32
18.35
19.73
81.81
68.31
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
60
- -
LT Borrowings
- -
903
- -
LT Finance Leases
- -
66
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
53
53
- -
Market Capitalization
4,558
4,971
4,783

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
831
- -
Cash, Cash Equivalents & STI
- -
217
- -
Accounts Receivable, Net
- -
195
- -
Inventories
- -
328
- -
Total Current Liabilities
- -
266
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
60
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.29%
11.99%
-12.35%
Free Cash Flow
8.5%
-0.23%
-14.22%
Net Income, GAAP
7.13%
-6.06%
-17.27%
Sales/Revenue/Turnover
10.01%
7.76%
0.81%
Total Cash Common Dividend
22.27%
4.07%
3.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
289
300
- -
- -
1,185
2025
313
306
- -
- -
1,195
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.86
0.94
- -
- -
3.49
2025
0.96
0.88
- -
- -
2.94
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.14
2025
- -
- -
- -
- -
1.2
2026
- -
- -
- -
- -
- -
Similar Companies
Intelligent Bio Solutions Inc. (INBS)
Medivolve Inc. (MEDVF)
Mettler-Toledo International Inc. (0K10.L)
Sourcebio International Plc (SBI.L)
Yourgene Health Plc (VILGF)
Precision System Science Co., Ltd. (7707.T)
Business
DiaSorin S.p.A. (DSRLF) develops, manufactures and markets reagent kits for in vitro diagnostics, specializing in immunodiagnostics and molecular diagnostics segments; immunodiagnostics assays cover infectious diseases, bone and mineral metabolism, endocrinology, hypertension, oncology, stool diagnostics, autoimmunity, brain and cardiac markers on automated LIAISON platforms including LIAISON XL, XS and PLEX multiplexing systems; molecular diagnostics products include Simplexa, NxTAG and LIAISON MDX assays for respiratory pathogens, gastrointestinal infections, bloodstream infections, C. auris, CMV, HSV, VZV, Bordetella and leukemia detection via platforms like LIAISON PLEX, ARIES and IAM; licensed technologies feature partnerships such as QuantiFERON-TB Gold Plus with QIAGEN, MeMed BV for bacterial/viral differentiation and B.R.A.H.M.S MR-proADM with Thermo Fisher. Founded in 1968 and headquartered in Saluggia, Italy, the company operates direct sales and production in continental Europe, Israel, the United States, Canada, Mexico, Brazil, China, India and Australia, with key subsidiaries including Luminex Corporation (acquired 2021 for molecular multiplexing), DiaSorin Molecular LLC and production sites in Madison WI, Cypress CA and Dietzenbach Germany. Recent developments include U.S. FDA 510(k) clearances in 2025 for LIAISON PLEX Gram-Positive Blood Culture Assay, Simplexa COVID-19/Flu A/B/RSV Direct kit, LIAISON PLEX Gram-Negative and Yeast Blood Culture Assays; new product launches such as LIAISON TSH-R Ab for Graves’ Disease, Simplexa C. auris direct assay and next-generation LIAISON QuantiFERON-TB Gold Plus II with QIAGEN; supplier agreement with Quest Diagnostics for LIAISON PLEX; project to discontinue Dietzenbach operations by 2026 for cost savings; H1 2025 revenues of €619 million (+5% YoY) and adjusted EBITDA of €214 million (+10% at CER), with revised FY2025 guidance confirming growth amid U.S. hospital expansion and European specialty tests.

Company News

APIChatGPT

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Head to Head Contrast: Perrigo (NYSE:PRGO) and DiaSorin (OTCMKTS:DSRLF)

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. DiaSorin (OTCMKTS:DSRLF)

  • defenseworld.net

    Head-To-Head Review: IM Cannabis (NASDAQ:IMCC) versus DiaSorin (OTCMKTS:DSRLF)

  • seekingalpha.com

    Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning

  • seekingalpha.com

    DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript

  • reuters.com

    Italy's DiaSorin ex-Covid revenue in line with guidance

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript

  • reuters.com

    Diasorin 2023 revenue drops 14%, in line with guidance; shares fall

  • zacks.com

    New Strong Sell Stocks for January 29th

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript

  • seekingalpha.com

    DiaSorin: Overvalued Italian Healthcare Company

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    DiaSorin's (DSRLF) CEO Carlo Rosa on Q1 2022 Results - Earnings Call Transcript

  • seekingalpha.com

    DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript